Kyverna Sets Pace In Race For Autoimmune CAR-T Approval By 2026
1. Kyverna Therapeutics focuses on cell therapies for autoimmune diseases, advancing KYV-101. 2. KYV-101 trials aim for FDA approval for stiff person syndrome and myasthenia gravis. 3. Kyverna has $211.7 million cash, ensuring operational funds through 2027. 4. Analyst expects KYV-101 will be the first CAR-T therapy for autoimmune diseases. 5. William Blair gives KYTX a fair value estimate of $27, indicating strong potential.